ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; IONIS AR 2.5Rx (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARRO-CITO
- 25 Apr 2019 Planned End Date changed from 1 Apr 2024 to 1 May 2024.
- 25 Apr 2019 Planned primary completion date changed from 1 Apr 2024 to 1 May 2024.
- 25 Apr 2019 Planned initiation date changed from 1 Apr 2019 to 1 May 2019.